Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Biosimilar Pathway Not Smooth For Some Early Applicants

Oct 22 2012

• By Derrick Gingery

Related Content

Biosimilars Pathway Dilemma: When Should Sponsors Pick (k) Before (a)?

May 23 2011

FDA “Busy” With Biosimilars; Sponsors Already In Pre-IND Meetings

May 16 2011

Biosimilar Podium Promotion: FDA Emphasizes Advantages Of Abbreviated Pathway

Oct 15 2012

FDA Sets Biosimilar Application Fees, But Is Silent On Volume Projections

Jul 31 2012

Teva’s G-CSF Product Clears FDA, Leaving Appeal Of Biosimilar Pathway Uncertain

Sep 03 2012

Biosimilar User Fee Meeting Schedule Allows FDA Data “Pre-Review”

Sep 17 2012

Additional Topics

United States Drug Approval Standards BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window